EAN Annual Congress

Jul 09, 2025

The SUNRISE trial underscores eptinezumab’s preventive efficacy and consistent tolerability profile in a largely Asian chronic migraine population, filling a critical data gap in global neurology care. Patients receiving eptinezumab were four times more likely to achieve a reduction of ≥75% in MMDs within the f...

Jul 09, 2025

ALMB-0166, a novel monoclonal antibody targeting connexin-43 hemichannels, demonstrates favorable safety and neurological recovery signals in acute SCI patients. Early-phase data support continued clinical development of ALMB-0166 as a potential neuroprotective and regenerative therapy following traumatic spina...

Jul 09, 2025

Adjunctive efgartigimod with intravenous methylprednisolone (IVMP) led to greater EDSS improvement and rapid IgG reduction in patients with acute NMOSD and MOGAD. Intensive dosing (20 mg/kg × 2) produced faster neurological recovery and greater antibody titer reductions. At EAN 2025, new data highlighted th...

Jul 09, 2025

Empasiprubart significantly delayed IVIg retreatment and improved grip strength and patient-reported outcomes in both MMN cohorts. Biomarker shifts, including reduced serum NfL levels, indicate axonal preservation and reinforce the neuroprotective potential of C2 inhibition. At European Academy of Neurology...

Jul 09, 2025

Riliprubart demonstrated meaningful clinical benefit across all enrolled cohorts—SoC-Treated, SoC-refractory, and SoC-naïve—with improvement in functional measures (INCAT, I-RODS, MRC-SS, grip strength). Encouraged by consistent Phase II results, two global Phase III trials in CIDP have now been launched, posit...